Results 71 to 80 of about 9,243 (198)

Does offering an incentive payment improve recruitment to clinical trials and increase the proportion of socially deprived and elderly participants? [PDF]

, 2015
BACKGROUND: Patient recruitment into clinical trials is a major challenge, and the elderly, socially deprived and those with multiple comorbidities are often underrepresented.
BC Martinson, BS Frey, CL Tishler, Claudine G Jennings, E Jones, EJ Emanuel, H Draper, IS Mackenzie, Isla S Mackenzie, J Saunders, JC Wong, Lewis McConnachie, Li Wei, Morris J Brown, N Dickert, PA Rochon, RM Titmuss, S Treweek, SD Halpern, Thomas M MacDonald, TM MacDonald   +20 more
core   +3 more sources

Effects of catechins, resveratrol, silymarin components and some of their conjugates on xanthine oxidase‐catalyzed xanthine and 6‐mercaptopurine oxidation

Journal of the Science of Food and Agriculture, Volume 105, Issue 5, Page 2765-2776, 30 March 2025.
Abstract BACKGROUND Over the past two decades, the global incidence of gout has markedly increased, affecting people worldwide. Considering the side effects of xanthine oxidase (XO) inhibitor drugs (e.g. allopurinol and febuxostat) used in the treatment of hyperuricemia and gout, the potential application of phytochemicals has been widely studied.
Tímea Bencsik, Orsolya Balázs, Róbert G Vida, Balázs Z Zsidó, Csaba Hetényi, Kateřina Valentová, Miklós Poór   +6 more
wiley   +1 more source

Long‐term remission in gout: Challenges and future opportunities

Rheumatology &Autoimmunity, EarlyView.
Prolonged hyperuricemia is a major risk factor for gout, which is now regarded as a curable disease. Awareness of the various factors that can trigger gout flares is essential for their prevention. An important determinant of treatment decisions and long‐term follow‐up is the quality of the clinician–patient relationship. The “treat‐to‐target” approach
Patapong Towiwat, Zhanguo Li
wiley   +1 more source

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age

BMC Geriatrics, 2012
Background The incidence of gout rises with increasing age. Management of elderly (≥65 years) gout patients can be challenging due to high rates of comorbidities, such as renal impairment and cardiovascular disease, and concomitant medication use ...
Jackson Robert L, Hunt Barbara, MacDonald Patricia A   +2 more
doaj   +1 more source

Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). [PDF]

, 2016
Determine the efficacy and safety of daily lesinurad (200 or 400 mg orally) added to allopurinol in patients with serum uric acid (sUA) above target in a 12-month, randomised, phase III trial.
Adler, S., Bardin, T., Baumgartner, S., Bhakta, N., Fung, M., Keenan, R.T., Khanna, P.P., Kopicko, J., So, A., Storgard, C.   +9 more
core   +1 more source

Identification and Characterization of Three Novel Biomarkers for Mixed/Cholestatic Drug‐Induced Liver Injury

Hepatology Research, EarlyView.
Three metabolites, pyroglutamylglycine (pyroGluGly), phenylalanine (Phe), and phenylalanyltryptophan (PheTrp), were identified as candidate DILI biomarkers. The serum concentrations of pyroGluGly, Phe, and PheTrp demonstrated a high differentiating ability in patients with mixed and cholestatic DILI compared with those in patients who recovered from ...
Kosuke Saito, Tatehiro Kagawa, Keiji Tsuji, Yuji Kumagai, Ken Sato, Shotaro Sakisaka, Naoya Sakamoto, Mitsuhiko Aiso, Shunji Hirose, Nami Mori, Toshio Uraoka, Kazuhide Takata, Koji Ogawa, Kazuhiko Mori, Motonobu Sato, Takayoshi Nishiya, Kazuhiko Takamatsu, Noriaki Arakawa, Takashi Izumi, Ruri Kikura‐Hanajiri, Yasuo Ohno, Yoshiro Saito, Hajime Takikawa   +22 more
wiley   +1 more source

An integrated population pharmacokinetic model of febuxostat in pediatric patients with hyperuricemia including gout and adult population of healthy subjects and patients with renal dysfunction

Pharmacology Research & Perspectives
The study objective was to validate febuxostat dosage and administration in pediatric patients with hyperuricemia including gout, using an integrated population pharmacokinetic (PopPK) analysis in the Japanese population.
Ryutaro Iwama, Kimie Nishida, Daisuke Ishii, Takeshi Iijima   +3 more
doaj   +1 more source

Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia

The Journal of Clinical Hypertension, 2021
Elevated serum uric acid is a cardiovascular risk factor in patients with hypertension, even when blood pressure (BP) is well controlled. Xanthine oxidoreductase inhibitors (XORi) reduce serum uric acid levels and have several other potential effects ...
Kazuomi Kario, Masafumi Nishizawa, Mari Kiuchi, Arihiro Kiyosue, Fumishi Tomita, Hiroshi Ohtani, Yasuhisa Abe, Hideyo Kuga, Satoshi Miyazaki, Takatoshi Kasai, Makiko Hongou, Takanori Yasu, Jin Kuramochi, Yoshihiro Fukumoto, Satoshi Hoshide, Ichiro Hisatome   +15 more
doaj   +1 more source

Risks Associated with Drug Treatments for Kidney Stones [PDF]

, 2015
Introduction: Renal stones are one of the most painful medical conditions patients experience. For many they are also a recurrent problem. Fortunately, there are a number of drug therapies available to treat symptoms as well as prevent future stone ...
Borofsky, Michael S., Lingeman, James E., York, Nadya   +2 more
core   +1 more source

POS0520 CARDIOVASCULAR SAFETY OF FEBUXOSTAT IN PATIENTS WITH GOUT OR HYPERURICEMIA: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS [PDF]

, 2023
R. Ghossan, O. Aitisha, Fouad Fayad, Pascal Richette, Thomas Bardin   +4 more
openalex   +1 more source